Catalyst Wire Dossier Catalyst Wire Dossier

Kesimpta (ofatumumab)

ofatumumab · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Kesimpta (ofatumumab), covering 2026-03-30 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation [Phase 4]

See pricing